These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10155326)

  • 1. The use of pharmaceuticals in critical care. The importance of outcome prediction models.
    Clifton GD; Blumenschein K
    Pharmacoeconomics; 1995 May; 7(5):388-92. PubMed ID: 10155326
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficiency-based pharmacotherapy: the new paradigm for the 21st century in medicine.
    Soto J
    Eur J Clin Pharmacol; 2000 Nov; 56(8):525-7. PubMed ID: 11151740
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents.
    Gazzaniga P; Garattini L
    Pharmacoeconomics; 1992 Oct; 2(4):270-8. PubMed ID: 10147042
    [No Abstract]   [Full Text] [Related]  

  • 4. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin.
    Lopert R; Lang DL; Hill SR
    J Clin Pharm Ther; 2003 Jun; 28(3):243-9. PubMed ID: 12795784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations.
    Clarke KW; Gray D
    Pharmacoeconomics; 1995 Apr; 7(4):280-3. PubMed ID: 10155317
    [No Abstract]   [Full Text] [Related]  

  • 8. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pharmacoeconomics in health policy and management in Norway.
    Grund J; Husbyn H
    Pharmacoeconomics; 1995 Jun; 7(6):475-83. PubMed ID: 10155333
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug prescribing issues in the intensive care unit: finding answers to common questions.
    Dasta JF
    Crit Care Med; 1994 Jun; 22(6):909-12. PubMed ID: 8205823
    [No Abstract]   [Full Text] [Related]  

  • 11. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis.
    Dere W; Avouac B; Boers M; Buxton M; Christiansen C; Dawson A; Gennari C; Guillemin F; Lawaetz H; Ornskov F; Roumagnac I; Reginster JY
    Calcif Tissue Int; 1998 Aug; 63(2):93-7. PubMed ID: 9685510
    [No Abstract]   [Full Text] [Related]  

  • 12. Indices of therapeutic outcome in pharmacoeconomic evaluation of drug therapy.
    Hurley SF
    Pharmacoeconomics; 1992 Mar; 1(3):155-60. PubMed ID: 10147026
    [No Abstract]   [Full Text] [Related]  

  • 13. The critical care pharmacist: what you get is more than what you see.
    Dasta JF; Jacob J
    Crit Care Med; 1994 Jun; 22(6):906-9. PubMed ID: 8205822
    [No Abstract]   [Full Text] [Related]  

  • 14. Special report: the value of pharmaceuticals. An "expensive" drug may be the most cost effective.
    Siegelman S
    Bus Health; 1991; [VALUE]():8-14. PubMed ID: 10170908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are drug too expensive in Canada? No.
    Williams R; Marion J
    Can Fam Physician; 2006 May; 52():573-6, 578-81. PubMed ID: 16739822
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapy evaluation, patient distribution, and cost-outcomes ratios.
    Langley PC
    Clin Ther; 1995; 17(2):341-7. PubMed ID: 7614534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics: therapeutic and economic considerations in treating the critically ill patient.
    Crane VS
    DICP; 1990 Nov; 24(11 Suppl):S24-7. PubMed ID: 2125394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidelines for performing a pharmacoeconomic analysis.
    Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
    Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug costs in intensive therapy].
    Boegel C
    Zentralbl Chir; 1985; 110(17):1082-6. PubMed ID: 4060911
    [No Abstract]   [Full Text] [Related]  

  • 20. The need to consider the cost factor of drugs in clinical trials.
    Reidenberg JW
    Clin Pharmacol Ther; 2003 May; 73(5):477-8. PubMed ID: 12732849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.